Chemotherapy and total-body irradiation followed by autologous lymphocyte infusion, aldesleukin, and autologous stem cell transplant in treating patients with metastatic melanoma

Journal of Drugs in Dermatology, May, 2007

Sponsored by National Cancer Institute (NCI). This phase II trial is studying how well chemotherapy and total-body irradiation followed by autologous lymphocyte infusion, aldesleukin, and autologous stem cell transplant, work in treating patients with metastatic melanoma.

Condition        Intervention                                  Phase

Melanoma (Skin)  Drug: aldesleukin                             Phase II
Nonmelanomatous  Drug: cyclophosphamide
  Skin Cancer    Drug: filgrastim
                 Drug: fludarabine phosphate
                 Drug: therapeutic tumor infiltrating
                   lymphocytes
                 Procedure: autologous bone marrow
                   transplantation
                 Procedure: autologous hematopoietic stem
                   cell transplantation
                 Procedure: biological therapy
                 Procedure: bone marrow ablation with stem
                   cell support
                 Procedure: bone marrow transplantation
                 Procedure: chemotherapy
                 Procedure: colony-stimulating factor therapy
                 Procedure: cytokine therapy
                 Procedure: hematopoietic stem cell mobilizer
                 Procedure: high-dose chemotherapy
                 Procedure: interleukin therapy
                 Procedure: leukocyte therapy
                 Procedure: peripheral blood stem cell
                  transplantation
                 Procedure: radiation therapy
                 Procedure: total-body irradiation
                 Procedure: tumor infiltrating lymphocyte
                   therapy

Study ID Numbers: CDR0000480141; NCI-06-C-0136; NCI-P6763

ClinicalTrials.gov Identifier: NCT00335127